Back to search
HR-positive,HER2-negative in Advanced Breast Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which HR-positive,HER2-negative in Advanced Breast Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which HR-positive,HER2-negative in Advanced Breast Cancer trials you may qualify forThe purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-can…
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- br…
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatmen…
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTO…
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimizati…
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization…
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with…